Get the Stockscreener App
6.03
3.25%
0.19
Pre-market:
6.17
0.14
+2.32%
Vir Biotechnology Inc stock is traded at $6.03, with a volume of 1.46M.
It is up +3.25% in the last 24 hours and down -6.07% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.84
Open:
$5.82
24h Volume:
1.46M
Relative Volume:
0.91
Market Cap:
$838.92M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.5383
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
-1.31%
1M Performance:
-6.07%
6M Performance:
+19.64%
1Y Performance:
-17.85%
1-Day Range:
$5.78
$6.065
1-Week Range:
$5.755
$6.12
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.03 | 812.49M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
What is HC Wainwright's Forecast for VIR FY2025 Earnings? - MarketBeat
Aug PreEarnings: Why Vir Biotechnology Inc stock remains resilientJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.4%Here's What Happened - MarketBeat
VIR: HC Wainwright & Co. Reiterates 'Buy' Rating with $15 Price Target | VIR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock By Investing.com - Investing.com Canada
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Vir Biotechnology Inc. stock beat market expectations this quarterEarnings Risk Report & Stepwise Trade Signal Implementation - Улправда
EV Market: Can Vir Biotechnology Inc. stock resist market sell offsEarnings Recap Summary & Precise Buy Zone Tips - Улправда
Aug Swings: Will Vir Biotechnology Inc stock benefit from M A activityOptions Play & Weekly Sector Rotation Insights - moha.gov.vn
Why analysts remain bullish on Vir Biotechnology Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Is Vir Biotechnology Inc. stock a buy for dividend growthJuly 2025 Highlights & Weekly Breakout Stock Alerts - Улправда
Momentum Shift: Can Vir Biotechnology Inc. stock beat market expectations this quarterJuly 2025 Highlights & Weekly Stock Breakout Alerts - Улправда
Can Vir Biotechnology Inc. stock sustain revenue growthQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - DonanımHaber
Will Vir Biotechnology Inc. stock outperform value stocks2025 Short Interest & Weekly High Return Stock Opportunities - DonanımHaber
Published on: 2025-12-19 13:20:41 - Улправда
How Vir Biotechnology Inc. stock performs after earnings2025 Trading Volume Trends & Technical Entry and Exit Tips - Улправда
Will Vir Biotechnology Inc. stock recover faster than market2025 Sector Review & Reliable Breakout Forecasts - Улправда
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Legal Desire Media and Insights
Vir Biotechnology stock gains on Norgine partnership for Hepatitis Delta program - Investing.com Canada
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology | Corporate - EQS News
Norgine Pharmaceuticals Limited - AD HOC NEWS
EQS-News: Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnologyboerse.de - boerse.de
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology - PR Newswire
Norgine Enhances Hepatology and Specialty Portfolio Through Exclusive In-Licensing Agreement with Vir Biotechnology - marketscreener.com
Vir Biotechnology Licenses CHD Combination Therapy to Norgine for Europe, Australia, New Zealand - marketscreener.com
Vir Biotechnology issues license to Norgine to market hepatitis D candidate - Seeking Alpha
Vir Biotechnology Secures Licensing Deal with Norgine - TipRanks
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal - Investing.com Canada
Vir Biotechnology licenses hepatitis delta treatment to Norgine in €550m deal By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Secures Exclusive Licensing Deal with No - GuruFocus
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology stock rises after licensing hepatitis delta treatment By Investing.com - Investing.com Canada
Vir Biotechnology grants Norgine exclusive commercial license to chronic hepatitis delta treatment candidate - marketscreener.com
Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate - TradingView — Track All Markets
Vir Biotechnology signs agreement with Norgine for hepatitis Delta treatment - Traders Union
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment - StreetInsider
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
Vir Biotechnology secures licensing deal with Norgine - MSN
Vir Biotechnology Earnings Notes - Trefis
12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC - MarketBeat
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com Canada
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal - Investing.com
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SATO VICKI L | Director |
Dec 01 '25 |
Sale |
6.00 |
22,000 |
132,070 |
1,188,391 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 26 '25 |
Sale |
6.39 |
127,938 |
817,652 |
13,982,271 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 28 '25 |
Sale |
6.44 |
61,493 |
396,015 |
13,920,778 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 25 '25 |
Sale |
6.38 |
235,971 |
1,505,495 |
14,110,209 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 24 '25 |
Sale |
6.15 |
227,803 |
1,400,783 |
14,346,180 |
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):